Medline (MDLN) vs Anbio Biotechnology (NNNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Medline is the larger company by market cap ($48.79 billion vs $204.5 million), about 238.5 times the size. On valuation, Anbio Biotechnology trades at a lower trailing P/E (31.1x vs 90.6x for Medline).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDLN | NNNN |
|---|---|---|
| Share price | $36.26 | $4.66 |
| Market cap | $48.79B | $204.53M |
| 1-day change | +1.45% | +0.87% |
| YTD return | -13.67% | -84.50% |
| 1-year return | — | -84.25% |
| P/E ratio (TTM) | 90.65 | 31.07 |
| Forward P/E | 23.00 | — |
| EPS (TTM) | $0.40 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $28.43B | — |
| Net income (latest FY) | $1.16B | — |
| Gross margin | 26.44% | — |
| Operating margin | 7.78% | — |
| Net margin | 4.08% | — |
| 52-week high | $50.88 | $44.73 |
| 52-week low | $31.49 | $4.16 |
| Distance from 52-week high | -28.73% | -89.58% |
| Analyst consensus | buy | — |
| Avg. price target upside | +22.50% | — |
| Average volume | 7.69M | 147.05K |
| Shares outstanding | 877.35M | 43.89M |
| Employees | 45,000 | 27 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Medline is about 238.5 times larger than Anbio Biotechnology by market value ($48.79B vs $204.53M).
- Medline trades at a higher earnings multiple (90.6x vs 31.1x trailing P/E).
About Medline
MDLN stock →Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally.
Health Care · Medical/Dental Instruments · 45,000 employees
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
MDLN vs NNNN FAQ
Which is bigger, Medline or Anbio Biotechnology?
Medline (MDLN) is larger, with a market capitalization of $48.79B compared with $204.53M for Anbio Biotechnology (NNNN).
Which has the lower P/E ratio, MDLN or NNNN?
NNNN has the lower trailing P/E at 31.1, versus 90.6 for MDLN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Medline and Anbio Biotechnology in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Medline and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Anbio Biotechnology.